Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug symbols : Ltrn save search
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: -1.05%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 1.21%
H: 2.91%
C: -7.88%
pharma drug key leaders development
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 7.05%
H: 1.85%
C: -1.03%
drug conference intelligence
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
Published: 2024-02-15 (Crawled : 15:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: -0.25%
H: 3.17%
C: -0.74%
pharma drug unique tumor program
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 2.81%
H: 0.0%
C: -1.74%
lp-284 fda pharma drug candidate designation lymphomas grants
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
Published: 2023-09-18 (Crawled : 23:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -3.69%
lp-284 fda pharma drug candidate clearance enabling lymphomas
Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting
Published: 2023-08-31 (Crawled : 14:30) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 0.21%
H: 1.05%
C: -4.84%
lp-284 pharma drug candidate lymphomas meeting
Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
Published: 2023-08-14 (Crawled : 14:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 2.04%
H: 0.0%
C: -4.0%
lp-184 rare pharma drug patent candidate treatment
Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 9.18%
H: 0.18%
C: -5.72%
lp-284 drug candidate cancer lymphomas
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
Published: 2023-06-12 (Crawled : 15:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 3.7%
H: 4.46%
C: 4.11%
lp-184 fda pharma drug candidate tumors clearance application
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
Published: 2023-06-08 (Crawled : 16:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 2.23%
H: 2.56%
C: 1.67%
radr pharma drug antibody collaboration
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
Published: 2023-04-13 (Crawled : 12:20) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 0.0%
H: 2.32%
C: 0.6%
lp-284 pharma drug patent candidate
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
Published: 2023-03-08 (Crawled : 13:20) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: -0.38%
H: 2.86%
C: -4.0%
pharma drug
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352
Published: 2023-02-27 (Crawled : 14:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 0.19%
H: 2.5%
C: 1.73%
ttc-352 pharma drug candidate collaboration
Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates
Published: 2023-02-15 (Crawled : 18:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 0.19%
H: 9.85%
C: 4.63%
radr pharma drug antibody
Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
Published: 2023-01-17 (Crawled : 14:20) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: -0.55%
H: 0.92%
C: -3.67%
lp-184 pharma drug candidate trial phase 1
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma
Published: 2023-01-05 (Crawled : 15:20) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: -7.58%
H: 4.01%
C: -4.71%
lp-284 fda designation pharma drug candidate grants
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting
Published: 2022-12-15 (Crawled : 14:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 2.04%
H: 1.81%
C: -0.91%
lp-284 pharma drug candidate meeting positive
Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)
Published: 2022-12-13 (Crawled : 14:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 0.19%
H: 7.56%
C: 1.74%
lp-184 pharma drug candidate breast symposium cancer negative
Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting
Published: 2022-11-22 (Crawled : 14:00) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 3.37%
H: 5.18%
C: -1.92%
lp-184 pharma drug candidate meeting positive glioblastoma
Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300
Published: 2022-10-20 (Crawled : 12:20) - biospace.com/
LTRN | News | $5.38 -6.76% -6.07% 98K
|
Health Technology
|
| O: 1.47%
H: 4.97%
C: -0.83%
lp-300 pharma drug patent candidate cancer
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.